Our data on the nephroprotective effects of SGLT2 inhibition by empagliflozin fits to previous findings in patients with diabetes (8–10) and also to findings in animal models of diabetic nephropathy (36–38) and even to findings in nondiabetic nephropathy models (39–43), However, there are also some studies showing no effect of SGLT2 inhibition in nondiabetic CKD models. This evidence concerns the gene SLC5A2 and chronic kidney disease.